"These emissions drive global warming, exacerbating the very respiratory conditions inhalers are meant to relieve," researchers wrote.

The U.S. Food and Drug Administration (FDA) approved sotatercept in March 2024 for treatment of pulmonary hypertension, according to the drug’s maker Merck. The drug is sold under the brand name ...

Nerandomilast is the first FDA-approved treatment for IPF in over a decade, targeting lung function decline. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of ...

Veterans with COPD and current tobacco use faced a reduced likelihood for tobacco dependence treatment if they lived in a rural area or had a long drive time to a specialty care facility, according to ...

GoodRx reports over 5.6 million Americans live in "pulmonology deserts," lacking accessible lung care, mostly in the central U.S.

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within ...

The use of anticoagulants is not associated with improved overall survival in patients with pulmonary arterial hypertension, a new study and an updated meta-analysis show.

A phase 3 trial evaluating benralizumab for the treatment of COPD did not meet its primary endpoint, according to AstraZeneca.

Dr. Rojas-Quintero is researching how Metformin, a long-used diabetes drug, may be able to slow fibrosis in the lungs.

The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations over 52 weeks by a relative 15.4% compared with placebo atop standard care (annualized rate 1.11 vs 1.31, P =0.049), ...